Am­gen and No­var­tis back Aimovig with new da­ta as mi­graine com­pe­ti­tion heats up

Fac­ing a slew of com­peti­tors, Am­gen and No­var­tis are march­ing out new Phase IV re­sults to bol­ster Aimovig, their first-to-mar­ket CGRP in­hibitor for mi­graine pre­ven­tion.

The re­sults come about a year and a half af­ter the drug was panned by a group of med­ical ex­perts who con­vened at Unit­ed­Health Group’s Op­tum­Rx of­fices, con­clud­ing it and two oth­er drugs had no clear ben­e­fit over ex­ist­ing treat­ments. The pan­el sug­gest­ed that US in­sur­ers im­pose lim­its on its use, as well as Te­va’s Ajovy and Eli Lil­ly’s Em­gal­i­ty, all ap­proved in 2018, ac­cord­ing to a Reuters re­port.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.